Income Statement (Annual)

GUAA / Guaranty Bancorp, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Interest And Dividend Income Operating
  Interest And Fee Income Loans And Leases 76,462 59,985 57,326 57,435 62,819 70,188 87,249 118,674
  Interest And Dividend Income Securities By Taxable Status
    Interest Income Securities Taxable 7,701 11,277 8,746 9,432 9,178 8,325 7,625 9,264
    Interest Income Securities Tax Exempt 2,662 2,066 2,558 2,990 2,708 2,852 3,683 4,933
  Dividend Income Operating 723 653 631 664 807 959 1,063 1,290
  Interest Income Federal Funds Sold And Securities Purchased Under Agreements To Resell 389 332 304 117 8 6 233 141
  Interest And Dividend Income Operating 87,937 74,313 69,565 70,638 75,520 82,330 99,853 134,302
Interest Expense
  Interest Expense Deposits 15,602 6,746 2,878 2,490 2,464 3,207 4,859 7,344
  Interest Expense Federal Funds Purchased And Securities Sold Under Agreements To Repurchase 132 74 67 49 40 45 52 71
  Interest Expense Federal Home Loan Bank And Federal Reserve Bank Advances Long Term 5,267 4,727 3,327 3,407 3,403 1,285 2,549 2,648
  Interest Expense Subordinated Notes And Debentures 2,581 2,872 2,882 1,122 800 814 2,005 3,440
  Interest Expense 23,582 14,419 9,154 7,068 6,707 5,351 9,465 13,503
Interest Income Expense Net 64,355 59,894 60,411 63,570 68,813 76,979 90,388 120,799
Provision For Loan And Lease Losses 34,400 5,000 -2,000 296 14 96 143 992
Interest Income Expense After Provision For Loan Loss 29,955 54,894 62,411 63,274 68,799 76,883 90,245 119,807
Noninterest Income
  Deposit Service And Other Fees - - 8,158 8,825 9,066 8,941 10,447 13,951
  Fees Generated From Management Of Customer Investments - 1,203 1,751 2,904 4,380 5,189 5,452 6,005
  Bank Owned Life Insurance Income - 609 576 1,018 1,295 1,758 2,005 2,559
  Gain Loss On Sale Of Securities Net 313 3,703 2,527 -11 28 132 -73 -6
  Gain Loss On Sales Of Loans Net 1,196 - 203 725 798 824 873 1,256
  Noninterest Income Other Operating Income - - - - - 336 553 1,679
  Noninterest Income 8,102 13,945 13,591 13,799 16,695 17,180 19,257 25,444
Noninterest Expense
  Labor And Related Expense 26,042 26,059 26,769 29,581 32,766 33,564 40,946 46,762
  Occupancy Net 7,399 7,513 7,253 6,289 6,308 6,312 5,887 6,664
  Equipment Expense 3,720 3,508 3,143 2,943 2,759 3,007 3,070 3,898
  Amortization Of Intangible Assets 5,168 4,091 3,138 2,818 2,506 1,981 1,557 2,745
  Other Real Estate Owned Expense Net - - - -1,160 367 80 31 174
  Insurance And Assessments 6,569 4,053 3,137 2,519 2,355 2,398 2,314 2,666
  Professional Fees 3,117 3,528 4,089 3,618 3,520 3,220 3,639 4,129
  Impairment Of Long Lived Assets Held For Use - - 2,750 - 186 122 185 394
  Other Noninterest Expense - - - - - 9,655 15,158 19,363
  Noninterest Expense 75,686 62,487 64,114 56,688 65,746 60,339 72,787 86,795
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -37,629 6,352 11,888 20,385 19,748 33,724 36,715 58,456
Income Tax Expense Benefit -6,290 - -3,171 6,356 6,236 11,270 11,988 19,832
Net Income Loss -31,339 6,352 15,059 14,029 13,512 22,454 24,727 38,624
Earnings Per Share Basic -0 -0 0 0 0 0 0 0
Earnings Per Share Diluted -0 -0 0 0 0 0 0 0
Common Stock Dividends Per Share Declared - - - 0 0 0 0 0
Weighted Average Number Of Shares Outstanding Basic 51,671 64,942 103,934 20,867 20,958 21,066 23,267 28,057
Weighted Average Number Of Diluted Shares Outstanding 51,671 64,942 104,391 20,951 21,087 21,272 23,560 28,344

Peers - State Commercial Banks (6022)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...